OESTROGEN-RECEPTOR INTERACTION IN TARGET TISSUES

被引:6
作者
JENSEN, EV
DESOMBRE, ER
机构
关键词
D O I
10.1042/bj1150028P
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
[No abstract available]
引用
收藏
页码:P28 / &
相关论文
共 50 条
[21]   The Role of CHK1 Varies with the Status of Oestrogen-receptor and Progesterone-receptor in the Targeted Therapy for Breast Cancer [J].
Xu, Wei ;
Huang, Minghua ;
Guo, Jia ;
Zhang, Huiting ;
Wang, Depeng ;
Liu, Tiantian ;
Liu, Hafting ;
Chen, Shiming ;
Gao, Peng ;
Mu, Kun .
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2020, 16 (08) :1388-1402
[22]   Association of oestrogen-receptor gene (ESR1) polymorphisms with migraine in the large Norfolk Island pedigree [J].
Rodriguez-Acevedo, Astrid J. ;
Maher, Bridget H. ;
Lea, Rodney A. ;
Benton, Miles ;
Griffiths, Lyn R. .
CEPHALALGIA, 2013, 33 (14) :1139-1147
[23]   Treatment with oestrogen-receptor agonists or oxytocin in conjunction with exercise protects against myocardial infarction in ovariectomized rats [J].
Bulut, Erman Caner ;
Abueid, Leyla ;
Ercan, Feriha ;
Suleymanoglu, Selami ;
Agirbasli, Mehmet ;
Yegen, Berrak C. .
EXPERIMENTAL PHYSIOLOGY, 2016, 101 (05) :612-627
[24]   CHARACTERISTICS OF INTERACTION OF THE ANTIANDROGEN FLUTAMIDE WITH THE ANDROGEN RECEPTOR IN VARIOUS TARGET TISSUES [J].
SIMARD, J ;
LUTHY, I ;
GUAY, J ;
BELANGER, A ;
LABRIE, F .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1986, 44 (03) :261-270
[25]   Co-designed weight management intervention for women recovering from oestrogen-receptor positive breast cancer [J].
Saxton, J. M. ;
Pickering, K. ;
Wane, S. ;
Humphreys, H. ;
Crank, H. ;
Anderson, A. S. ;
Cain, H. ;
Cohen, J. ;
Copeland, R. J. ;
Gray, J. ;
Hargreaves, J. ;
McNally, R. J. Q. ;
Wilson, C. .
BMC CANCER, 2022, 22 (01)
[26]   Co-designed weight management intervention for women recovering from oestrogen-receptor positive breast cancer [J].
J. M. Saxton ;
K. Pickering ;
S. Wane ;
H. Humphreys ;
H. Crank ;
A. S. Anderson ;
H. Cain ;
J. Cohen ;
R. J. Copeland ;
J. Gray ;
J. Hargreaves ;
R. J. Q. McNally ;
C. Wilson .
BMC Cancer, 22
[27]   Low Her2-expression as predictor of outcome in oestrogen-receptor (ER) positive metastatic breast cancer (MBC) [J].
Bergen, E. ;
Berghoff, A. S. ;
Rudas, M. ;
Minichsdorfer, C. ;
Dubsky, P. ;
Sattlberger, C. ;
Mader, R. M. ;
Fitzal, F. ;
Gnant, M. ;
Zielinski, C. C. ;
Preusser, M. ;
Steger, G. G. ;
Bartsch, R. .
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 :262-263
[28]   Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males [J].
Ongphiphadhanakul, B ;
Rajatanavin, R ;
Chanprasertyothin, S ;
Piaseu, N ;
Chailurkit, L .
CLINICAL ENDOCRINOLOGY, 1998, 49 (06) :803-809
[29]   A phase III trial to determine the activity and safety of fulvestrant (Faslodex®) in premenopausal women with oestrogen-receptor positive breast cancer [J].
Robertson, JFR ;
Lanza, C .
EUROPEAN JOURNAL OF CANCER, 2002, 38 :S97-S97
[30]   INTERACTION OF CALCITONIN AND CALCITONIN GENE RELATED PEPTIDE AT RECEPTOR-SITES IN TARGET TISSUES [J].
GOLTZMAN, D ;
MITCHELL, J .
SCIENCE, 1985, 227 (4692) :1343-1345